MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells

Tamoxifen is commonly used to treat patients with ESR/ER-positive breast cancer, but its therapeutic benefit is limited by the development of resistance. Recently, alterations in macroautophagy/autophagy function were demonstrated to be a potential mechanism for tamoxifen resistance. Although MTA1 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Min-Ho, Koh, Dahae, Na, Hyelin, Ka, Na-Lee, Kim, Seungsu, Kim, Hyeon-Ji, Hong, Sungyoul, Shin, Young Kee, Seong, Je Kyung, Lee, Mi-Ock
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Paper - Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070012/
https://www.ncbi.nlm.nih.gov/pubmed/29130361
http://dx.doi.org/10.1080/15548627.2017.1388476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070012/
https://www.ncbi.nlm.nih.gov/pubmed/29130361
http://dx.doi.org/10.1080/15548627.2017.1388476

Ejemplares similares